Cerevance launched with new technology, drug portfolio and $36M in cash to tackle brain diseases.
Takeda Pharmaceutical Company Limited and Lightstone Ventures announced the launch of Cerevance, a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric disorders. The company will use a new technology, created in the Howard Hughes Medical Institute laboratory of Nathaniel Heintz, Ph.D. at the Rockefeller University.
Takeda will jumpstart the new company by providing a 25-person neuroscience research team from its Cambridge, U.K. site, including industry veteran Mark Carlton, Ph.D., fully equipped laboratory space, and licenses to a portfolio of preclinical and clinical stage drug programs. Cerevance is funded with $36 million that includes a $21.5 million Series A financing investment from Takeda and Lightstone Ventures, with each joining Cerevance’s board of directors.
“Seven of the ten leading causes of disability in the world are central nervous system disorders,” said Brad Margus, Cerevance chief executive officer. “With a well capitalized, proven team and promising drug programs already underway, we hope to rapidly advance a pipeline of therapeutics into the clinic in parallel with scaling up a truly novel approach to brain diseases based on our new technology.”
“We are thrilled to assemble some of our best scientists, programs and discovery resources in a highly focused endeavor as part of our increased emphasis on leveraging external innovation,” said Andrew Plump, M.D., Ph.D., chief medical and scientific officer of Takeda. “When we announced the closure of our research site in Cambridge, U.K., our goal was to find an innovative externalization home for our most promising CNS (central nervous system) programs and scientists in an entrepreneurial setting. Cerevance is a great example of our new R&D strategy.”
“Lightstone is excited to lead the Series A in Cerevance and believes the combination of Nat Heintz’s expertise and platform technology, the proven and impassioned management team, and Takeda’s strong support represent a compelling early-stage investment opportunity,” said Jason Lettmann, partner at Lightstone Ventures. “Cerevance is in a unique position to bring a breakthrough technology to the development of treatments for central nervous system diseases that affect millions of people worldwide.”
This is not the first time that Takeda, Heintz and Margus have joined forces. In 2009, Takeda invested in and later collaborated with CNS drug discovery start-up Envoy Therapeutics which included Heintz and Margus as founders and which also licensed a technology from the Rockefeller University. Takeda ultimately acquired Envoy in 2012.
Cerevance will have sites in both Massachusetts and the United Kingdom, surrounded by vibrant academic research ecosystems that support biotechnology and pharmaceutical companies.
(Source: Business Wire)
Filed Under: Drug Discovery
